The Impact of the Covid-19 Pandemic on New and Ongoing Clinical Trials
Navigating the COVID-19 Pandemic, Preparing for the Rest of 2020 & Planning a Return to "Normalcy" in the New Clinical Trial Landscape 

June 25 - 26, 2020 | Virtual Event

Meet the Speakers

View the event program for additional information on speakers, sessions, networking activities, and more!

Speakers


Len Rosenberg PhD, RPh
Len Rosenberg PhD, RPh
Head, Clinical Operations
Beat AML/LLS
Leslie Jebson
Leslie Jebson
Executive Director, Clinical Strategy
Texas A&M Health
Diane Maloney
Diane Maloney
Associate Director Policy, Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)
Rose Gerber
Rose Gerber
Director of Patient Advocacy and Education
Community Oncology Alliance (COA)
Jennifer Healey
Jennifer Healey
Head of Global Medical Operations
Sanofi
Jeff Douglas
Jeff Douglas
Head of Clinical Operations
MyoKardia
Craig Lipset
Craig Lipset
Fmr. Head of Clinical Innovation
Pfizer
Steffen Thirstrup MD, PhD
Steffen Thirstrup MD, PhD
Fmr. Head of Division, Medicines Assessment and Clinical Trials
Danish Health and Medicines Authority
Heiner Gertzen
Heiner Gertzen
Head GxP Inspection & Audit Readiness
Sanofi
Tim Hagerty
Tim Hagerty
VP Development & Business Operations
Dantari